MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.
about
The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-AnalysisTP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.Therapy-related myeloid neoplasms: pathobiology and clinical characteristicsNational Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Subsequent NeoplasmsA high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysisRadiation-induced apoptosis varies among individuals and is modified by sex and age.Natural selection and functional genetic variation in the p53 pathway.Opposite roles of NMDA receptors in relapsing and primary progressive multiple sclerosisGenetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors.Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivorsSubsequent malignant neoplasms after hematopoietic cell transplantation.Second malignancies after multiple myeloma: from 1960s to 2010s.Treatment-related myelodysplastic syndrome: molecular characteristics and therapyTherapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature.Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma.Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies.Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilityTherapy-related myelodysplasia and acute myeloid leukemiaThe evolving challenge of therapy-related myeloid neoplasms.An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia.Drug Development Against Metastatic CancersIdentification and functional analysis of acute myeloid leukemia susceptibility associated single nucleotide polymorphisms at non-protein coding regions of RUNX1.Association Between TP53 Gene Codon 72 Polymorphism and Acute Myeloid Leukemia Susceptibility: Evidence Based on a Meta-Analysis.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair.Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.Fanconi anemia gene variants in therapy-related myeloid neoplasms.Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study.Allogeneic Hematopoietic Stem Cell Transplantation In Therapy-Related Myeloid Neoplasms (t-MN) of the Adult: Monocentric Observational Study and Review of the Literature.TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.Clinical impact of SNP of P53 genes pathway on the adult AML patients.MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls
P2860
Q26781492-C8A965B2-C85B-42F8-A318-6863A21EF7EAQ27853319-FDDE473C-9CDE-496E-9F9E-EBB3077361D4Q28386366-363B8DCA-0100-4990-82FA-E4D434B0BCD5Q29248394-B9D95009-3841-49C5-A0E3-76601E2D1F60Q34148472-58FCC99D-6C15-44A9-8425-69D71FFFD996Q34430158-266CEE10-3521-4ACD-805B-2681B665942DQ34463885-549916EC-6CF4-4700-A5AE-C3A53C4F8DFBQ34718094-65A3A765-C293-4433-851B-4406DB46E3C4Q34807095-FB72BE78-8EDB-48E3-9AE0-224D89E0D4CCQ35117677-21E774D0-3940-4356-96A5-A8C285224F52Q35169579-80A8FA6C-5B9D-44A1-BD2B-F80574319A7FQ35327266-4FC4DC43-798C-4805-A387-8BE23FB05392Q35678455-BFAA535E-D864-4C25-BD83-52D197A8B1B0Q35891594-22733FE3-8100-4766-B975-A717BED21EFAQ36219790-2DDA84CB-3889-4BDF-8409-520A28A757DEQ36335336-3D3950AF-6ADC-44B7-BD24-334894CF3EFEQ36438206-AFF1257C-D8B2-4F14-B8B0-58A4328683C1Q36773931-74C77C2F-6EE9-40EB-9355-B888B6D17E40Q37209075-5F635ED7-3102-45EB-B4E4-D75F87D644ADQ37402657-247C716A-98A6-4001-87DD-A8E302B68A1AQ37576054-16992057-8A15-4FB5-8131-C3DE2FABF4AFQ37855227-0956B0A1-0EFF-463C-8833-A180D267BAF3Q38052129-2841DD58-9302-43B8-AE1D-96D4AA69499BQ38323624-3498F286-DA2C-434D-90A3-80D4A2367185Q38737865-63654AB4-3FB7-42A1-AF33-672DD74B4DCAQ38835022-BEB6362C-AF36-4F50-B7C1-CF6BDA7C2B8CQ38954993-D02947D7-004C-4AE2-9E10-19CD0A7642A5Q39013620-F0B48031-65D3-422F-910B-E2D533D300EFQ42195101-D49FDDD8-31A9-4A80-9FAE-75BB46B2DB13Q42325010-743016BD-3391-438F-8A67-8E06F324FF24Q42421841-32BE3B74-3C58-4980-80EE-4E30D8239773Q44176860-4F2289E6-747C-4728-99D3-BEB3D05A0375Q47799677-5CBD1F47-D858-469A-BAD9-87144A29C03AQ48177963-6F75D3BD-A255-4C30-B0BF-8B7822F919E3Q49233865-E5E91E9C-6103-4775-A6A2-1D3537F65E82Q50450550-EA5B18AB-D9F7-4DB9-9C67-BA8E9165C642Q50631404-F5E47ACE-6364-4A8D-9CC7-5921F30267EEQ50864357-AA776CAE-CB81-443C-81E2-DBF5AC7E1F3CQ57636601-69B7ACA4-0819-4D2E-8284-0C41F50F0E99
P2860
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
MDM2 SNP309 and TP53 Arg72Pro ...... eloid leukemia susceptibility.
@en
type
label
MDM2 SNP309 and TP53 Arg72Pro ...... eloid leukemia susceptibility.
@en
prefLabel
MDM2 SNP309 and TP53 Arg72Pro ...... eloid leukemia susceptibility.
@en
P2093
P2860
P1433
P1476
MDM2 SNP309 and TP53 Arg72Pro ...... eloid leukemia susceptibility.
@en
P2093
Dezheng Huo
James M Allan
Kenan Onel
Lisa J Worrillow
Mekhala Banerjee
Michelle M Le Beau
Nathan A Ellis
Ozlem Yildiz
Richard A Larson
P2860
P304
P356
10.1182/BLOOD-2007-11-126508
P407
P577
2008-04-21T00:00:00Z